- Open Access
Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin
© Spee et al; licensee BioMed Central Ltd. 2006
- Received: 16 December 2005
- Accepted: 05 September 2006
- Published: 05 September 2006
Apoptosis resistance occurs in various tumors. The anti-apoptotic XIAP protein is responsible for inhibiting apoptosis by reducing caspase-3 activation. Our aim is to evaluate whether RNA inhibition against XIAP increases the sensitivity of canine cell-lines for chemotherapeutics such as TRAIL and doxorubicin. We used small interfering RNA's (siRNA) directed against XIAP in three cell-lines derived from bile-duct epithelia (BDE), mammary carcinoma (P114), and osteosarcoma (D17). These cell-lines represent frequently occurring canine cancers and are highly comparable to their human counterparts. XIAP down-regulation was measured by means of quantitative PCR (Q-PCR) and Western blotting. The XIAP depleted cells were treated with a serial dilution of TRAIL or doxorubicin and compared to mock- and nonsense-treated controls. Viability was measured with a MTT assay.
All XIAP siRNA treated cell-lines showed a mRNA down-regulation over 80 percent. Western blot analysis confirmed mRNA measurements. No compensatory effect of IAP family members was seen in XIAP depleted cells. The sensitivity of XIAP depleted cells for TRAIL was highest in BDE cells with an increase in the ED50 of 14-fold, compared to mock- and nonsense-treated controls. The sensitivity of P114 and D17 cell-lines increased six- and five-fold, respectively. Doxorubicin treatment in XIAP depleted cells increased sensitivity in BDE cells more than eight-fold, whereas P114 and D17 cell-lines showed an increase in sensitivity of three- and five-fold, respectively.
XIAP directed siRNA's have a strong sensitizing effect on TRAIL-reduced cell-viability and a smaller but significant effect with the DNA damaging drug doxorubicin. The increase in efficacy of chemotherapeutics with XIAP depletion provides the rationale for the use of XIAP siRNA's in insensitive canine tumors.
- P114 Cell
- Doxorubicin Hydrochloride
- Hypoxanthine Phosphoribosyl Transferase
- Bile Duct Epithelial
- Canine Mammary Tumor
The inhibitor of apoptosis proteins (IAPs) are a family of structurally related proteins with anti-apoptotic functions. To date, eight family members have been identified all carrying a functional baculovirus IAP repeat (BIR) domain. Members of the IAP family include Survivin, c-IAP1, c-IAP2, and X-linked inhibitor of apoptosis (XIAP) which directly bind and inhibit caspases 3, 7, and 9 . XIAP (hILP/MIHA/BIRC4) is the most potent caspase inhibitor of all family members [2, 3]. XAF1 and Smac/DIABLO regulate XIAP activity, which indicates an important function of this protein in maintaining proper apoptotic functions within the cell.
Apoptosis can be initiated via the intrinsic and/or the extrinsic pathway . The intrinsic pathway is activated by intracellular stress such as growth factor withdrawal, hypoxia, and DNA damage. In this pathway the caspase cascade is triggered by cytochrome c release from the mitochondria. On the other hand the extrinsic apoptotic pathway is triggered by death receptors such as Fas/CD95, TNF receptor, and the TRAIL receptor. Activation of these death receptors usually involves caspase 8 activation which in turn activates effector caspases-3 and -7 [5, 6]. Overall, activation of these two pathways is not distinctly separated as activation of one usually involves the other.
Resistance to apoptosis is a hallmark of various (canine) cancers . Indeed in various (chemoresitant) tumors the XIAP protein has been shown to be induced when compared to normal tissue [7–9]. XIAP knock-out mice have shown that the absence of XIAP does not have a negative effect on the development of normal tissues . On the other hand, down-regulation of XIAP with antisense techniques provides antitumor activity in non-small-cell lung cancer (NSCLC) xenografts . Furthermore studies with stable expression of short-hairpin RNAs (shRNA) against XIAP dramatically increased sensitivity of cell-lines to chemotherapies . Thus, XIAP may represent a novel and tumor-selective therapeutic target for anticancer drug design .
In this study we describe the use of siRNA's directed against XIAP for sensitizing canine cell-lines to TRAIL and doxorubicin reduced cell-viability. Whereas TRAIL treatment will provide proof of principle, sensitizing tumor cells to doxorubicin will greatly benefit the use of this chemotherapeutical in canine tumors. We chose three cell-lines derived from bile duct-, mammary-, and bone tumor-tissue which could provide the basis for the therapeutic use of siRNA's. Taken together, in order develop anti-neoplastic therapeutic protocols in dog tumors, which represent good clinical models , we investigated the effect of XIAP siRNA on different apoptotic agents in canine tumor cell-lines.
Establishing a XIAP down-regulation
Gene expression of IAP family members and cellular homeostasis
In the present study we observed a strong decrease of TRAIL- and doxorubicin-induced cell viability with XIAP siRNA in canine cell-lines. We have used three different tumor cell-lines in order to be able to conclude about the general applicability of the outcomes of this study. The first cell-line studied, a canine liver epithelial cell-line of biliary origin (BDE) can be considered as an in vitro counterpart of cholangiocarcinoma. The P114 cell-line was derived from a mammary tumor , and the third cell-line was derived from a canine osteosarcoma (D17). In order to show the proof of principle that XIAP depletion in canine cell-lines decreases the sensitivity to anti-neoplastic drugs, a treatment with TRAIL was used. As TRAIL solely induces apoptosis through the extrinsic pathway, an increase in sensitivity will show a decreased capacity of inhibiting caspase-3 and -7. Second doxorubicin, a DNA damaging drug which type is frequently being used for treatment of canine tumors, was used.
Although we did not see an reduction of cell-viability in our cell-lines when XIAP was down-regulated (data not shown), as described by several papers [16, 17], we could demonstrate an increase in the sensitivity for different chemotherapeutic treatments. The fact that the introduction of XIAP siRNA's alone does not seem to reduce cell-viability indicates a need for triggering the cells by chemotherapy. XIAP has been proposed as a possible treatment of various cancers . Our results showed a strong increase in sensitivity of all three tumor cell-lines to TRAIL treatment up to fourteen fold in XIAP siRNA treated BDE cells. This indicates that the measured results represent a general effect. The fact that all canine cell-lines were increasingly sensitized through XIAP depletion holds promises that therapeutic low concentrations TRAIL may be effectively used without effecting somatic cells.
Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is commonly used in veterinary clinical treatments for various cancers . However, many dog tumors appear to be resistant to doxorubicin. In the in vitro experiments of Macy et al. , five out of twenty-one carcinomas were deemed sensitive (24 %), whereas three out of thirteen (23 %) sarcomas showed sensitivity to a 14 day treatment with 1 μg/ml doxorubicin. Because of this insensitivity to high amounts of doxorubicin, a pretreatment with XIAP siRNA could be beneficial for many canine tumors, lowering the concentrations needed for a beneficial effect in sensitive tumors and could even make insensitive tumors treatable. Although this added effect remains to be proven in vivo, the application of siRNA's against XIAP in combination with a chemotherapeutic agent such as doxorubicin seems a realistic option based on the present results. In vivo experiments with siRNA's already have been used in various models [21–24]. In these experiments results show that injected siRNA's are stable and can be found in the blood for long periods, down-regulating long half-life proteins over several days . However, the use of targeted drug-delivery systems should still be considered for siRNA delivery  or chemotherapy , which further enhances specificity and potentially reduces drug-associated side-effects.
Measurements on gene expression of IAP family members and cellular homeostasis genes did not reveal major differences in cell-cycle progression. In the P114 cell-line, however, the introduction of siRNA's in general seemed to induce the cell-cycle and cellular viability. Although this may imply an adverse effect in vivo the MTT measurements did not reveal differences in viability of the groups (data not shown). The IAP family members under study (besides XIAP) did not show many significant differences in gene-expression. In D17 cells however, a significant increase in c-IAP1 and Smac/Diablo was seen in the nonsense-treated cells. The effect of these differences remains elusive, but the antagonistic properties of these proteins could explain why little if any effect was observed in cell viability. Taken together, some differences were seen in cellular homeostasis or IAP family members although the majority indicated an absence of off-target effects. However, unpublished results on TRAIL-treated cells did show differences in gene-expression in c-IAP1. When treated for 5 hours with 50 ng/ml TRAIL, c-IAP1 induced two to three-fold in the D17 cell-line and six to seven-fold in the P114 cell-line, whereas no effect was seen in the BDE cells. This indicates that the reduction in XIAP mRNA when treated with TRAIL, could be counteracted with an increase in c-IAP1. Furthermore, the cell-line with the highest induction in c-IAP1 (seven-fold increase in P114) has the least sensitivity for TRAIL treatment. This result corroborates the hypothesis as described by Harlin et al. where XIAP knock-out mice did not show any negative side effects during development . In this paper no compensation due to increased gene-expression of other family members such as c-IAP1 was seen in untreated cells with XIAP depletion.
The use of siRNA's directed against XIAP to increase chemosensitivity of tumors has been described in several papers [28–30]. Furthermore, clinical trials have started with antisense oligonucleotides to treat solid tumors and hematologic malignancies by Aegera pharmaceuticals (Montreal, Canada) . This study not only corroborates the found results in these papers, the use of osteosarcoma and breast carcinoma derived cell lines could indicate other fields of interest. Concerns mentioned in these papers indicate the possible role of other IAP family members after the targeting of XIAP. As mentioned previously, in the tumor cell lines chosen here, no compensatory effect was seen in the IAP family members indicating a possible positive outcome in the treatment of these tumors.
The use of spontaneously occurring tumors in companion animals as models for human cancer has already been described previously . In this study several tumor cell lines have been suggested as models that offer the best comparative interest, including canine osteosarcoma and mammary tumors. Canine mammary tumour, canine osteosarcoma and possibly also canine hepatocellularcarcinoma  resemble human pathologies at the molecular level. Especially the first two are relatively frequently observed in dogs. Therefore we had chosen these cell lines as in vitro models for a-proof-of-principle. These in vitro results provide a rational for the use of XIAP inhibition (either with siRNA or other small molecules) in in vivo therapies in dogs.
The use of XIAP siRNA to increase the sensitivity of canine tumors for chemotherapy holds great potential. In this study we showed an increase in sensitivity in canine cell-lines derived from osteosarcoma, mammary carcinoma, and cholangiocarcinoma for TRAIL and Doxorubicin reduced cell-viability. These in vitro results provide a rational for the use of XIAP siRNA in in vivo therapeutical use in dogs.
Canine bile duct epithelial (BDE) cells were acquired from the Amsterdam Medical Center, Experimental Liver cell bank (Amsterdam, The Netherlands) . BDE cells were grown in DMEM (Life Technologies, Inc., Invitrogen, Breda, The Netherlands) supplemented with 580 mg/l glutamine, 10 μg/ml gentamicin, and 10% heat-inactivated fetal bovine serum (FBS; Harlan Sera-Lab, Loughborough, United Kingdom) at 37°C in a humidified atmosphere of 5% CO2 in air. P114 canine mammary tumor cells were acquired from Dr. Rutteman from the department of clinical sciences of companion animals, faculty of veterinary medicine, Utrecht university, the Netherlands. P114 cells were grown in DMEM:F12 medium (Invitrogen, Breda, The Netherlands) containing 580 mg/l glutamine, 10 μg/ml gentamicin, and 10% FBS at 37°C in a humidified atmosphere of 5% CO2 in air . The canine osteosarcoma cells (D17) were acquired from the American Type Culture Collection (ATCC, Cat.no. CRL-6248) and were maintained in DMEM medium (Invitrogen) supplemented with 580 mg/l glutamine, 10 μg/ml gentamicin, and 10% FBS at 37°C in a humidified atmosphere of 5% CO2 in air. For all experiments cells were seeded in a concentration of 4 × 103 cells per well in a 96-well plate 24 hours before transfection.
Establishment of the down-regulation of XIAP in canine tumor cell-lines
For silencing experiments, Stealth™ dsRNA molecules were obtained from Invitrogen. A specific sequence for canine XIAP silencing (5'-CCAUGUGCUAUACAGUCAUUACUUU-3') was selected after general recommendations (Invitrogen) and was designed from the canine XIAP gene sequence (Genbank accession no. AY603038). A nonsense sequence was used as a negative control (5'-GCAGGUGCUAGUACAAGUCCGACAA-3'). Transfection was performed with the Magnet Assisted Transfection (MATra) technique (IBA BioTAGnology/Westburg b.v., Leusden, The Netherlands), in combination with lipofectamine2000™ (Invitrogen), according to the manufacturer's instructions. In short, 50 nM siRNA molecules were transfected into the cell-lines in the presence of an optimized concentration Lipofectamin2000™ (1.2 μl/ml), for 20 minutes on the plate magnet under cell-culture conditions. After transfection, growth media including antibiotics replaced the transfection media. Control samples were mock transfected with lipofectamine2000™ and magnetic beads from the MATra technique.
For TRAIL treatment, a serial dilution of 400 to 0 ng/ml recombinant TRAIL (R&D Systems Europe Ltd., Abingdon, United Kingdom) was used in DMEM media (Invitrogen) including 10 % FCS, glutamine (580 mg/l), and gentamycin (10 μg/ml). Treatment started 48 hours after transfection. After a 24 hour treatment proliferation and viability was measured with a MTT assay (5 mg/ml). For doxorubicin treatment, a serial dilution of 100 to 0 μg/ml doxorubicin hydrochloride (Pharmachemie b.v., Haarlem, The Netherlands) was used diluted in growth medium. Treatment started 48 hours after transfection. After 24 hour treatment proliferation and viability was measured with a MTT assay (5 mg/ml). The experiment was repeated four times, averages of the four independent experiments were used in the analysis. Statistical significance of differences in viability of the XIAP siRNA treated cell-lines at different drug concentrations compared to control cells were determined by an one-way ANOVA using the Dunnett multiple comparisons test. P < 0.05 was considered to indicate statistical significance. Analysis was performed using SPSS software (SPSS Benelux, Gorinchem, the Netherlands).
RNA isolation and Reverse-transcription polymerase chain reaction
For each group (control, XIAP siRNA, or nonsense siRNA) the RNA of six independent experiments was isolated. Total cellular RNA was isolated with the Qiagen RNeasy Mini Kit according to the manufacturer's instructions (Qiagen, Leusden, The Netherlands). In short, RNA was isolated from each sample by adding 100 μl lysis buffer (RLT containing 1 % (v/v) β-mercaptoethanol) directly after decanting the media. The RNA samples were treated with DNase-I (Qiagen RNase-free DNase kit). In total 3 μg of RNA were incubated with poly(dT) primers at 42°C for 45 min, in a 60 μl reaction volume, using the Reverse Transcription System from Promega (Promega Benelux, Leiden, The Netherlands).
Quantitative measurements of the mRNA levels
Nucleotide Sequences of Canine Specific Primers for Real-Time Quantitative PCR.
Product size (bp)
TGT CCC CAC CCC CAA TGT ATC
CTC CGA TGC CTG CTT CAC TAC CTT
AGC TTG CTG GTG AAA AGG AC
TTA TAG TCA AGG GCA TAT CC
ACT ATG TAT CAC TTG AGG CTC TGG TTT C
AGT CTG GCT TGA TTC ATC TTG TGT ATG
AGG CGT CCC CGT GTC CGA GAG
TAG CAT CAG GCC GCA GCA GAA GC
AGG CCA ATG TAA TTA ATA AAC AGG A
AAC TAA GAC AGT ATC AAT CAG TTC TCT C
AGC AGA AGC TGC ATA TCA AAC TGG AG
ACT TCC TGC ACC TGC GAC TTC AC
GCC CCT CCT CAG CAT CTC ATC
GGC TCA TAA GGC ACC ACC ACA C
ATC ACT GAA GAT GGA TGG GTT GGT
GAA AGG AGC ATG TTC TGA AGT AGC ACT
TGG AGA GCG TCA ACC GGG AGA TGT
AGG TGT GCA GAT GCC GGT TCA GGT
CGG AGG GAC GCC AAA CAG G
GTC CCG GGT CAA CTC TTC GTG
ACT ACC TGA ACC GCT
CGG ATG GAG TTG TCA
Western blot analysis
Samples were homogenized in 350 μl RIPA buffer containing 1 % Igepal, 0.6 mM Phenylmethylsulfonyl fluoride, 17 μg/ml aprotinine and 1 mM sodium orthovanadate (Sigma chemical Co., Zwijndrecht, The Netherlands) for 30 minutes on ice. Protein concentrations were obtained using a Lowry-based assay (DC Protein Assay, BioRad, Veenendaal, The Netherlands). Fifteen μg of protein of the supernatant were denatured for 3 min at 95°C and electroforesed on 15 % Tris-HCl polyacrylamide gels (BioRad) and the proteins were transferred onto Hybond-C Extra Nitrocellulose membranes (Amersham Biosciences Europe, Roosendaal, The Netherlands) using a Mini Trans-Blot® Cell blot-apparatus (BioRad). The procedure for immunodetection was based on an ECL Western blot analysis system, performed according to the manufacturer's instructions (Amersham Biosciences Europe). The membranes were incubated with 4 % ECL blocking solution and 0.1 % Tween 20 (Boom B.V., Meppel, The Netherlands) in TBS for 1 hour under gentle shaking. Primary antibodies were incubated at 4°C overnight. For XIAP a mouse anti-dog XIAP (BD Biosciences, Alphen aan den Rijn, The Netherlands) was used in a dilution of 1:1,000 in TBST with 4% BSA. As a loading control a mouse anti-dog Beta-Actin antibody was used in a 1:2,000 dilution in TBST with 4% BSA. After washing, the membranes were incubated with a goat anti-mouse (R&D Systems/Westburg b.v.) in TBST with 4% BSA for 1 hour at room temperature. Exposures were made with Kodak BioMax Light-1 films (Sigma chemical Co.).
The authors would like to thank Dr. Erik Teske for his assistance in the statistical work.
- Nachmias B, Ashhab Y, Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004, 14: 231-243. 10.1016/j.semcancer.2004.04.002View ArticlePubMedGoogle Scholar
- Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997, 388: 300-304. 10.1038/40901View ArticlePubMedGoogle Scholar
- Stennicke HR, Ryan CA, Salvesen GS: Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci. 2002, 27: 94-101. 10.1016/S0968-0004(01)02045-XView ArticlePubMedGoogle Scholar
- Kim R: Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005, 103: 1551-1560. 10.1002/cncr.20947View ArticlePubMedGoogle Scholar
- Bergman PJ: Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract. 2003, 33: 651-667. 10.1016/S0195-5616(03)00004-4View ArticlePubMedGoogle Scholar
- Boatright KM, Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 2003, 15: 725-731. 10.1016/j.ceb.2003.10.009View ArticlePubMedGoogle Scholar
- Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol. 2002, 128: 554-560. 10.1007/s00432-002-0364-zView ArticlePubMedGoogle Scholar
- Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003, 9: 4914-4925.PubMedGoogle Scholar
- Shiraki K, Sugimoto K, Yamanaka Y, Yamaguchi Y, Saitou Y, Ito K, Yamamoto N, Yamanaka T, Fujikawa K, Murata K, Nakano T: Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med. 2003, 12: 705-708.PubMedGoogle Scholar
- Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB: Characterization of XIAP-deficient mice. Mol Cell Biol. 2001, 21: 3604-3608. 10.1128/MCB.21.10.3604-3608.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, Lacasse EC: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res. 2003, 9: 2826-2836.PubMedGoogle Scholar
- McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004, 23: 8105-8117. 10.1038/sj.onc.1207967View ArticlePubMedGoogle Scholar
- Huang Y, Lu M, Wu H: Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers?. Cancer Cell. 2004, 5: 1-2. 10.1016/S1535-6108(03)00340-4View ArticlePubMedGoogle Scholar
- Vail DM, MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18: 781-792.View ArticlePubMedGoogle Scholar
- van Leeuwen I, Hellmen E, Cornelisse CJ, Van den BB, Rutteman GR: P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res. 1996, 16: 3737-3744.PubMedGoogle Scholar
- Amantana A, London CA, Iversen PL, Devi GR: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004, 3: 699-707.PubMedGoogle Scholar
- Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004, 5: 25-35. 10.1016/S1535-6108(03)00332-5View ArticlePubMedGoogle Scholar
- Wang S, El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003, 22: 8628-8633. 10.1038/sj.onc.1207232View ArticlePubMedGoogle Scholar
- Cagliero E, Ferracini R, Morello E, Scotlandi K, Manara MC, Buracco P, Comandone A, Baroetto PR, Baldini N: Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep. 2004, 12: 1023-1031.PubMedGoogle Scholar
- Macy DW, Ensley BA, Gillette EL: In vitro susceptibility of canine tumor stem cells to doxorubicin. Am J Vet Res. 1988, 49: 1903-1905.PubMedGoogle Scholar
- Scherr M, Morgan MA, Eder M: Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem. 2003, 10: 245-256.View ArticlePubMedGoogle Scholar
- Sorensen DR, Leirdal M, Sioud M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 2003, 327: 761-766. 10.1016/S0022-2836(03)00181-5View ArticlePubMedGoogle Scholar
- Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004, 64: 3365-3370. 10.1158/0008-5472.CAN-03-2682View ArticlePubMedGoogle Scholar
- Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kuhnel F, Kubicka S: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A. 2003, 100: 7797-7802. 10.1073/pnas.1330920100PubMed CentralView ArticlePubMedGoogle Scholar
- Dykxhoorn DM, Novina CD, Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003, 4: 457-467. 10.1038/nrm1129View ArticlePubMedGoogle Scholar
- Gilmore IR, Fox SP, Hollins AJ, Sohail M, Akhtar S: The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J Drug Target. 2004, 12: 315-340. 10.1080/10611860400006257View ArticlePubMedGoogle Scholar
- Ma Y, Manolache S, Denes FS, Thamm DH, Kurzman ID, Vail DM: Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery. J Biomater Sci Polym Ed. 2004, 15: 1033-1049. 10.1163/1568562041526441View ArticlePubMedGoogle Scholar
- Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, Chen Z, Li J: XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 2006, 32: 288-296. 10.1097/01.mpa.0000218314.67111.fbView ArticlePubMedGoogle Scholar
- Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K, Nakano T: Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep. 2005, 14: 1311-1316.PubMedGoogle Scholar
- Zhang Y, Wang Y, Gao W, Zhang R, Han X, Jia M, Guan W: Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2006, 96: 267-277. 10.1007/s10549-005-9080-0View ArticlePubMedGoogle Scholar
- Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer. 2005, 92: 532-538.PubMed CentralPubMedGoogle Scholar
- Schimmer AD, Dalili S, Batey RA, Riedl SJ: Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006, 13: 179-188. 10.1038/sj.cdd.4401826View ArticlePubMedGoogle Scholar
- Boomkens SY, Spee B, Ijzer J, Kisjes R, Egberink HF, van I, Rothuizen J, Penning LC: The establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patterns. Comp Hepatol. 2004, 3: 9- 10.1186/1476-5926-3-9PubMed CentralView ArticlePubMedGoogle Scholar
- Oda D, Savard CE, Nguyen TD, Eng L, Swenson ER, Lee SP: Dog pancreatic duct epithelial cells: long-term culture and characterization. Am J Pathol. 1996, 148: 977-985.PubMed CentralPubMedGoogle Scholar
- Spee B, Mandigers PJ, Arends B, Bode P, van I, Hoffmann G, Rothuizen J, Penning LC: Differential expression of copper-associated and oxidative stress related proteins in a new variant of copper toxicosis in Doberman pinschers. Comp Hepatol. 2005, 4: 3- 10.1186/1476-5926-4-3PubMed CentralView ArticlePubMedGoogle Scholar
- Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3: RESEARCH0034- 10.1186/gb-2002-3-7-research0034PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.